Cargando…

Airway remodelling rather than cellular infiltration characterizes both type2 cytokine biomarker‐high and ‐low severe asthma

BACKGROUND: The most recognizable phenotype of severe asthma comprises people who are blood eosinophil and FeNO‐high, driven by type 2 (T2) cytokine biology, which responds to targeted biological therapies. However, in many people with severe asthma, these T2 biomarkers are suppressed but poorly con...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khalfaoui, Latifa, Symon, Fiona A., Couillard, Simon, Hargadon, Beverley, Chaudhuri, Rekha, Bicknell, Steve, Mansur, Adel H., Shrimanker, Rahul, Hinks, Timothy S. C., Pavord, Ian D., Fowler, Stephen J., Brown, Vanessa, McGarvey, Lorcan P., Heaney, Liam G., Austin, Cary D., Howarth, Peter H., Arron, Joseph R., Choy, David F., Bradding, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790286/ https://www.ncbi.nlm.nih.gov/pubmed/35579040 http://dx.doi.org/10.1111/all.15376

Ejemplares similares

Fractional Exhaled Nitric Oxide Nonsuppression Identifies Corticosteroid-Resistant Type 2 Signaling in Severe Asthma
por: Couillard, Simon, et al.
Publicado: (2021)

The relationship between the Leicester cough questionnaire, eosinophilic airway inflammation and asthma patient related outcomes in severe adult asthma
por: Natarajan, Sushiladevi, et al.
Publicado: (2017)

Sub‐stratification of type‐2 high airway disease for therapeutic decision‐making: A ‘bomb’ (blood eosinophils) meets ‘magnet’ (FeNO) framework
por: Couillard, Simon, et al.
Publicado: (2022)

ACE2, TMPRSS2, and furin gene expression in the airways of people with asthma—implications for COVID-19
por: Bradding, Peter, et al.
Publicado: (2020)

Objective and Subjective Measurement of Cough in Asthma: A Systematic Review of the Literature
por: Holmes, Joshua, et al.
Publicado: (2022)

Adverse perception of cough in patients with severe asthma: a discrete choice experiment
por: Holmes, Joshua, et al.
Publicado: (2023)

Body Mass and Fat Mass in Refractory Asthma: An Observational 1 Year Follow-Up Study
por: Bafadhel, Mona, et al.
Publicado: (2010)

An observational study to determine the relationship between cough frequency and markers of inflammation in severe asthma
por: Holmes, Joshua, et al.
Publicado: (2022)

Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial
por: Heaney, Liam G, et al.
Publicado: (2021)

Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma
por: Busby, John, et al.
Publicado: (2022)

Chronic cough: new insights and future prospects
por: Morice, Alyn, et al.
Publicado: (2021)

A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial
por: Hanratty, Catherine E., et al.
Publicado: (2018)

Mechanisms and Rationale for Targeted Therapies in Refractory and Unexplained Chronic Cough
por: Mazzone, Stuart B., et al.
Publicado: (2020)

Longitudinal changes in sputum and blood inflammatory mediators during FeNO suppression testing
por: Couillard, Simon, et al.
Publicado: (2022)

Recent progress in the management of chronic cough
por: Song, Woo-Jung, et al.
Publicado: (2020)

Reply to Weinberger
por: Birring, Surinder S., et al.
Publicado: (2023)

The role of oral methotrexate as a steroid sparing agent in refractory eosinophilic asthma
por: Bilocca, David, et al.
Publicado: (2017)

COUGH: consolidating a mature field for the next 5 years
por: Chung, Kian Fan, et al.
Publicado: (2011)

Review of Drug Development Guidance to Treat Chronic Obstructive Pulmonary Disease: US and EU Perspectives
por: van Haarst, Aernout, et al.
Publicado: (2019)

Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide
por: Couillard, Simon, et al.
Publicado: (2022)

Prevalence of psychomorbidity among patients with chronic cough
por: McGarvey, Lorcan PA, et al.
Publicado: (2006)

Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype Oxford Asthma Attack Risk Scale (ORACLE)
por: Couillard, Simon, et al.
Publicado: (2021)

Acute Respiratory Distress Syndrome Caused by Mycoplasma Pneumoniae Diagnosed by Polymerase Chain Reaction
por: Yew, Peter, et al.
Publicado: (2012)

Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK)
por: Heaney, Liam G, et al.
Publicado: (2016)

From bench to bedside: The role of cough hypersensitivity in chronic cough
por: Drake, Matthew G., et al.
Publicado: (2023)

Human Lung Mast Cells Impair Corticosteroid Responsiveness in Human Airway Smooth Muscle Cells
por: Alzahrani, Abdulrahman, et al.
Publicado: (2021)

Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough
por: Muccino, David R., et al.
Publicado: (2020)

Clinical Research Fellow
por: Addy, Charlotte, et al.
Publicado: (2019)

Treating acute cough: wet versus dry – have we got the paradigm wrong?
por: Morice, Alyn H., et al.
Publicado: (2015)

Discordance in investigator-reported and adjudicated sudden death in TIOSPIR
por: Wise, Robert A., et al.
Publicado: (2017)

In vitro, in silico and in vivo study challenges the impact of bronchial thermoplasty on acute airway smooth muscle mass loss
por: Chernyavsky, Igor L., et al.
Publicado: (2018)

Glucocorticoid toxicity reduction with mepolizumab using the Glucocorticoid Toxicity Index
por: McDowell, P. Jane, et al.
Publicado: (2022)

Early-phase clinical trials in a pandemic: learning from the response to COVID-19
por: Horsley, Alex, et al.
Publicado: (2022)

Absence of Adverse Effects of Tiotropium/Olodaterol Compared with the Monocomponents on Long-Term Heart Rate and Blood Pressure in Patients with Moderate-to-Very-Severe COPD
por: Andreas, Stefan, et al.
Publicado: (2020)

Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups
por: Smith, Jaclyn A., et al.
Publicado: (2022)

Asthma in pregnancy: An update
por: Couillard, Simon, et al.
Publicado: (2020)

Blood eosinophils, fractional exhaled nitric oxide and the risk of asthma attacks in randomised controlled trials: protocol for a systemic review and control arm patient-level meta-analysis for clinical prediction modelling
por: Couillard, Simon, et al.
Publicado: (2022)

Effect of aclidinium bromide on cough and sputum symptoms in moderate-to-severe COPD in three phase III trials
por: McGarvey, Lorcan, et al.
Publicado: (2016)

Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat(®) device for maintenance treatment of COPD: comparison with the long-acting β(2)-agonist formoterol
por: Koch, Andrea, et al.
Publicado: (2017)

Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks
por: Birring, Surinder S., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dhh898ka5l4u6t1ra3ms803mib